S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, 2008.

E. Houot, R. Morschhauser, F. Sonet, A. Brice, P. Belhadj et al., Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma, Haematologica, vol.98, pp.1107-1114, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00933219

R. Morin, N. Johnson, T. Severson, A. Mungall, J. An et al., Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin, Nature Genetics, vol.22, issue.2, pp.181-185, 2010.
DOI : 10.4049/jimmunol.164.1.1

L. Pasqualucci, D. Dominguez-sola, A. Chiarenza, G. Fabbri, A. Grunn et al., Inactivating mutations of acetyltransferase genes in B-cell lymphoma, Nature, vol.5, issue.7337, pp.189-195, 2011.
DOI : 10.4161/epi.5.1.10449

A. Pastore, V. Jurinovic, R. Kridel, E. Hoster, A. Staiger et al., Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, The Lancet Oncology, vol.16, issue.9, pp.1111-1122, 2015.
DOI : 10.1016/S1470-2045(15)00169-2

E. Viré, C. Brenner, R. Deplus, L. Blanchon, M. Fraga et al., The Polycomb group protein EZH2 directly controls DNA methylation, Nature, vol.439, issue.7078, pp.871-874, 2006.
DOI : 10.1038/sj.emboj.7600509

R. , W. L. Wang, H. Xia, L. Erdjument-bromage, H. Tempst et al., Role of histone H3 lysine 27 methylation in Polycomb-group silencing, Science, vol.298, pp.1039-1043, 2002.

R. Margueron and D. Reinberg, The Polycomb complex PRC2 and its mark in life, Nature, vol.6, issue.7330, pp.343-349, 2011.
DOI : 10.1016/j.stem.2010.04.013

J. Okosun, C. Bödör, J. Wang, S. Araf, C. Yang et al., Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma, Nature Genetics, vol.61, issue.2, pp.176-181, 2014.
DOI : 10.1371/journal.pgen.1002691

C. Bödör, V. Grossmann, N. Popov, J. Okosun, C. O-'riain et al., EZH2 mutations are frequent and represent an early event in follicular lymphoma, Blood, vol.122, issue.18, pp.3165-3168, 2013.
DOI : 10.1182/blood-2013-04-496893

C. Sneeringer, M. Scott, K. Kuntz, S. Knutson, R. Pollock et al., Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas, Proceedings of the National Academy of Sciences, vol.377, issue.4, pp.20980-20985, 2010.
DOI : 10.1016/j.ymeth.2003.11.016

D. , C. J. Berg, T. Schapira, M. Cheng, S. Moradian et al., Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation, Blood, vol.117, pp.2451-2459, 2011.

M. Mccabe, H. Ott, G. Ganji, S. Korenchuk, C. Thompson et al., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations, Nature, vol.22, issue.7427, pp.108-112, 2012.
DOI : 10.1016/0006-2952(73)90196-2

W. Béguelin, R. Popovic, M. Teater, Y. Jiang, K. Bunting et al., EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation, Cancer Cell, vol.23, issue.5, pp.677-692, 2013.
DOI : 10.1016/j.ccr.2013.04.011

G. Souroullas, W. Jeck, J. Parker, J. Simon, J. Liu et al., An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation, Nature Medicine, vol.21, issue.6, pp.632-640, 2016.
DOI : 10.1073/pnas.0506580102

M. Caganova, C. Carrisi, G. Varano, F. Mainoldi, F. Zanardi et al., Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis, Journal of Clinical Investigation, vol.123, issue.12, pp.5009-5022, 2013.
DOI : 10.1172/JCI70626DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973104

S. Knutson, S. Kawano, Y. Minoshima, N. Warholic, K. Huang et al., Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma, Molecular Cancer Therapeutics, vol.13, issue.4, pp.842-854, 2014.
DOI : 10.1158/1535-7163.MCT-13-0773

W. Qi, H. Chan, L. Teng, L. Li, S. Chuai et al., Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation, Proceedings of the National Academy of Sciences, vol.4, issue.2, pp.21360-21365, 2012.
DOI : 10.1093/biostatistics/4.2.249

S. Dubois, S. Mareschal, J. Picquenot, P. Viailly, E. Bohers et al., Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?, Oncotarget, vol.6, issue.18, pp.16712-16724, 2015.
DOI : 10.18632/oncotarget.3154

Z. Zhou, J. Gao, R. Popovic, K. Wolniak, V. Parimi et al., Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation, Leukemia & Lymphoma, vol.8, issue.10, pp.2895-2901, 2015.
DOI : 10.1073/pnas.1210371110

D. Horsman, J. Connors, T. Pantzar, and R. Gascoyne, Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18), Genes, Chromosomes and Cancer, vol.107, issue.4, pp.375-382, 2001.
DOI : 10.1016/S0002-9440(10)65630-1

G. Salles, J. Seymour, F. Offner, A. López-guillermo, D. Belada et al., Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, issue.9759, pp.42-51, 2011.
DOI : 10.1016/S0140-6736(10)62175-7

D. Kim, G. Pertea, C. Trapnell, H. Pimentel, R. Kelley et al., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions, Genome Biology, vol.14, issue.4, p.36, 2013.
DOI : 10.1186/gb-2009-10-3-r25

A. Mckenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis et al., The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data, Genome Research, vol.20, issue.9, pp.1297-1303, 2010.
DOI : 10.1101/gr.107524.110

S. Anders, P. Pyl, and W. Huber, HTSeq--a Python framework to work with high-throughput sequencing data, Bioinformatics, vol.31, issue.2, pp.166-169, 2015.
DOI : 10.1093/bioinformatics/btu638
URL : https://academic.oup.com/bioinformatics/article-pdf/31/2/166/7000027/btu638.pdf

M. Love, W. Huber, and S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biology, vol.14, issue.12, p.550, 2014.
DOI : 10.1186/gb-2013-14-4-r36

T. Popova, E. Manié, D. Stoppa-lyonnet, G. Rigaill, E. Barillot et al., Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays, Genome Biology, vol.10, issue.11, p.128, 2009.
DOI : 10.1186/gb-2009-10-11-r128
URL : https://hal.archives-ouvertes.fr/inserm-00663915

Y. Benjamini and Y. Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J R Stat Soc Ser B, vol.57, pp.289-300, 1995.

A. Subramanian, P. Tamayo, V. Mootha, S. Mukherjee, B. Ebert et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proceedings of the National Academy of Sciences, vol.19, issue.18, pp.15545-15550, 2005.
DOI : 10.1093/bioinformatics/btg363
URL : http://www.pnas.org/content/102/43/15545.full.pdf

C. Casulo, M. Byrtek, K. Dawson, X. Zhou, C. Farber et al., Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study, Journal of Clinical Oncology, vol.33, issue.23, pp.2516-2522, 2015.
DOI : 10.1200/JCO.2014.59.7534

M. Maurer, E. Bachy, H. Ghesquières, S. Ansell, G. Nowakowski et al., Early event status informs subsequent outcome in newly diagnosed follicular lymphoma, American Journal of Hematology, vol.78, issue.11, pp.1096-1101, 2016.
DOI : 10.1080/01621459.1983.10477915
URL : https://hal.archives-ouvertes.fr/hal-01492002

I. Velichutina, R. Shaknovich, H. Geng, N. Johnson, R. Gascoyne et al., EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis, Blood, vol.116, issue.24, pp.5247-5255, 2010.
DOI : 10.1182/blood-2010-04-280149
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012542

A. Louissaint, K. Schafernak, J. Geyer, A. Kovach, M. Ghandi et al., Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations, Blood, vol.128, issue.8, pp.1093-1100, 2016.
DOI : 10.1182/blood-2015-12-682591
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000844